• SA25 Caregiver Burden in Growth Hormone Deficiency: A Targeted Review

    Dec 1, 2023, 00:00

  • HPR123 Risk Sharing Agreements in the Asia-Pacific Region: A Systematic Literature Review on New Pricing Modalities to Improve Value Access

    Dec 1, 2023, 00:00

  • EE518 An Updated Cost-Effectiveness Analysis of Axicabtagene Ciloleucel in Second-Line Large B-Cell Lymphoma Patients in the United States

    Dec 1, 2023, 00:00

  • EE148 Are General Population Utilities Appropriate to Use as Baselines for Age-Adjustment of Utility Values?

    Dec 1, 2023, 00:00

  • PT26 How Aware Are Biotech and Pharmaceutical Companies of the Implementation of the New EU HTA?

    Dec 1, 2023, 00:00

  • EE627 The Potential Value of Identifying Type 2 Diabetes Subgroups in the CPRD Cohort for Guiding Intensive Treatment: A HTx Study Comparing Novel Data-Driven Clustering to Traditional Risk-Driven Subgroups

    Dec 1, 2023, 00:00

  • EE80 Cost-Effectiveness of Ribociclib Plus a Non-Steroidal Aromatase Inhibitor for the Treatment of Pre- and Peri-Menopausal Women with HR+/HER2 Advanced Breast Cancer in Turkey

    Dec 1, 2023, 00:00

  • HTA282 Evolution of Timeframes Within the Overall Time-to-Market Since Marketing Authorisation for New Innovative-Presumed Products in France Since the First Published Economic Opinion

    Dec 1, 2023, 00:00

  • HTA345 Amplifying the Patient Voi Characterising the Impact of Patient and Clinician Engagement (PACE) Meetings on SMC Decision Making

    Dec 1, 2023, 00:00

  • PCR133 Patient Experience of Second-Line Treatment for Relapsed/Refractory Chronic Lymphocytic Leukaemia in UK Clinical Practi Study Methodology

    Dec 1, 2023, 00:00

  • EE705 The Healthcare Resource Utilisation and Associated Costs for Patients with Newly Diagnosed Fragile X Syndrome

    Dec 1, 2023, 00:00

  • PCR55 Unleashing the Power of Social Media Listening: A Promising Tool for Patient-Focused Research

    Dec 1, 2023, 00:00

  • PT32 Cost-Effectiveness of Lorlatinib in Second-Line Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer in China

    Dec 1, 2023, 00:00

  • HSD55 Sex Differences in Guideline Adherence for Coronary Angiography in Patients with Suspected Chronic Coronary Artery Disease in Germany: Insights from the ENLIGHT-KHK Trial

    Dec 1, 2023, 00:00

  • EPH24 Changes in Prescribing of Systemic Cancer Therapies in England: A Nationwide Analysis of Community and Hospital Medicines Utilisation

    Dec 1, 2023, 00:00

  • PCR68 Estimation of Minimal Clinically Important Difference (MCID) for the Tardive Dyskinesia Impact Scale (TDIS), a Tardive Dyskinesia-Specific Patient-Reported Outcome

    Dec 1, 2023, 00:00

  • RWD100 Comparison of Real-World Safety and Effectiveness of Mepolizumab and Benralizumab in the Management of Severe Asthma: A Systematic Review

    Dec 1, 2023, 00:00

  • MSR125 How Prognostic Factors Are Identified for Population Matching Analysis

    Dec 1, 2023, 00:00

  • MT72 Effectiveness of Drone Technology on Access to Blood and Its Product in the Eastern Region of Ghana: A Cross-Sectional Study

    Dec 1, 2023, 00:00

  • HTA250 Mapping the VF-14 Onto the EQ-5D-5L: The Potential to Estimate Quality-Adjusted Life-Years Without Generic Quality-of-Life Data in Ophthalmology

    Dec 1, 2023, 00:00

  • HTA357 Cost-Comparisons, an Easier Route to NICE Recommendations?

    Dec 1, 2023, 00:00

  • EE194 Economic Evaluation of Tofacitinib for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis in Greece

    Dec 1, 2023, 00:00

  • EPH31 Systematic Literature Review on the Global Epidemiology of Angelman Syndrome

    Dec 1, 2023, 00:00

  • HSD95 Unmet Needs and Value Proposition for Genital Warts Novel Treatments: Payer Perception

    Dec 1, 2023, 00:00

  • PCR181 Health-Related Quality-of-Life of Patients Treated with Repotrectinib for Neurotrophic Tyrosine Receptor Kinase (NTRK)-Positive Advanced Solid Tumors: Results from TRIDENT-1

    Dec 1, 2023, 00:00

  • HPR132 The Role of Economic Evaluation in HTA in Spain

    Dec 1, 2023, 00:00

  • The Relationship Between Pharmaceutical Innovation and Cancer Mortality in Spain, From 1999 to 2016

    Dec 1, 2023, 00:00

  • EE498 Cost-per-Responder Analysis of Bimekizumab Vs Other Licensed Anti-Interleukin Therapies in Psoriatic Arthritis from a UK Perspective

    Dec 1, 2023, 00:00

  • PCR7 People Living With HIV’s Lived Experiences of Long-Acting Injectable Antiretroviral Treatment Administrations in France Show the Central Role of Hospital Nurses in Care: A Qualitative Study (PANTER)

    Dec 1, 2023, 00:00

  • CO27 The Feasibility of Systematic Goal Quality Assurance During Goal Attainment Scaling in a Rare Disease

    Dec 1, 2023, 00:00

  • EE422 Health Economic Modelling of Current Population Health Management Interventions for CKD in the UK Using a Population-Level Markov Model

    Dec 1, 2023, 00:00

  • EE86 Healthcare Resource Utilization (HCRU) and Associated Costs Among Patients with Acute Myeloid Leukemia (AML) Treated with Oral Azacitidine as Maintenance and Those Eligible but Not Treated Using a US Claims Database

    Dec 1, 2023, 00:00

  • EE559 The Burden of Disease of Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Honduras, El Salvador, Dominican Republic

    Dec 1, 2023, 00:00

  • EPH116 Patient Pathways and Economics of Tumor-Related Hypothalamic Obesity in Germany—A Representative Claims Data Analysis

    Dec 1, 2023, 00:00

  • PCR173 Identifying Behaviors Practiced By Individuals to Avoid COVID-19: Development of the Content of the Physical Distancing Scale – COVID-19 (PDS-C19)

    Dec 1, 2023, 00:00

  • OP10 The Ripple Effects of Healthcare Reforms in Germany: A Reduced Free Pricing Period

    Dec 1, 2023, 00:00

  • MSR20 Estimating Undetected Medication Errors at Care Transitions: A Framework to Support Decision-Making

    Dec 1, 2023, 00:00

  • PCR177 Assessing the Impact of Relapses on Patient Outcomes in NMOSD

    Dec 1, 2023, 00:00

  • HPR53 Timely Reimbursement: The Impact of Early Access Programmes in Non-Squamous Non-Small Cell Lung Cancer

    Dec 1, 2023, 00:00

  • HTA196 HTA Guidance Updates and Usage of Real-World Evidence (RWE) in Reimbursement Decisions—A 2023 Perspective

    Dec 1, 2023, 00:00

  • EPH78 A Review of Patient-Reported Outcomes and External Control Arms in Regulatory Submissions of Novel Oncology Drugs

    Dec 1, 2023, 00:00

  • PCR139 'We Have Conversations That Other Couples Don′t Have to Have:' A Qualitative Study of the Impact of Caregiving in Friedreich Ataxia (FA)

    Dec 1, 2023, 00:00

  • MSR78 Use of External Control Data to Adjust for Treatment Switching in Cost-Effectiveness Analyses: Lisocabtagene Maraleucel (Liso-Cel) Versus Standard of Care (SOC) in Second-Line Relapsed or Refractory Large B-Cell Lymphoma

    Dec 1, 2023, 00:00

  • EE155 Economic Burden of Obstructive Hypertrophic Cardiomyopathy in France

    Dec 1, 2023, 00:00

  • HTA321 Factors Influencing the Shi Costs of Orphan Drugs After Their Renewed Regular Benefit Assessment Due to Exceeding the Sales Threshold in Germany

    Dec 1, 2023, 00:00

  • EE487 Cost-Effectiveness Analysis of Isavuconazole Versus Liposomal Amphotericin for the Treatment of Invasive Mucormycosis in Jordan

    Dec 1, 2023, 00:00

  • MSR32 Tips for Excel(lent) Modelling or R There Better Alternatives?

    Dec 1, 2023, 00:00

  • HPR120 Investigating the Nature and Scope of Innovative Payment and Pricing Schemes for Health Technologies

    Dec 1, 2023, 00:00

  • PCR36 Building a COA Strategy in Allergic Fungal Rhinosinusitis: Patient Experiences and Clinical Outcome Assessments from the Literature

    Dec 1, 2023, 00:00

  • EE642 The Costs of Oral Antiviral Delivery in UK Clinical Practi Expert Opinion Survey

    Dec 1, 2023, 00:00

  • HPR136 Designing an Effective Bundle Payment Program for Osteoarthritis

    Dec 1, 2023, 00:00

  • CO42 4P Care and Adjusting Therapy for Hypothyroidism – A Potential to Reduce Costs of Healthcare and Loss of Productivity

    Dec 1, 2023, 00:00

  • EPH215 Informal Caregiving and Illicit Drug Use in England and Wales

    Dec 1, 2023, 00:00

  • P50 Joint Modelling of Intermediate Longitudinal Biomarkers to Predict Overall Survival in Patients with Solid Tumors

    Dec 1, 2023, 00:00

  • EE216 Provision and Public Expenditure of Radiotherapy Services in Greece (2013-2020)

    Dec 1, 2023, 00:00

  • EE558 The Cost-Effectiveness of Budesonide/Formoterol Maintenance and Reliever Therapy Versus Salmeterol/Fluticasone Plus As-Needed Salbutamol Among Asthma Patients ≥12 Years in China

    Dec 1, 2023, 00:00

  • Health Service Delivery Process of Care

    Dec 1, 2023, 00:00

  • EE296 Should Hospitals Do Contract Research? Costs, Net Monetary Benefit, and Return on Public Sector Investments in Research at Kuopio University Hospital

    Dec 1, 2023, 00:00

  • MSR120 A Method for Adjusting US Health State Utilities for Use in the UK

    Dec 1, 2023, 00:00

  • PCR172 Physical Distancing to Avoid COVID-19 and the Association With Humanistic Burden in Immunocompromised Adults – The Eagle Study

    Dec 1, 2023, 00:00

  • PCR226 Health Related Quality of Life and Health Utility Values Across Different Levels of Physically Distancing Behaviors to Avoid COVID-19 in Immunocompromised Adults – The Eagle Study

    Dec 1, 2023, 00:00

  • EE475 Economic Burden on Diabetes and Cardiovascular Disease: Real World Data and Empirical Analysis in Algeria

    Dec 1, 2023, 00:00

  • EE721 Ferric Carboxymaltose in the Treatment of Iron Deficiency Anemia in Patients with Pregnancy, Inflammatory Bowel Disease, Heart Failure and Bariatric Surgery Under the Payer’s Perspective of the Supplementary System in Brazil

    Dec 1, 2023, 00:00

  • MT21 Clinical Application of Circulating Tumor Cells in Melanoma Patients: Overview of Current Available Data

    Dec 1, 2023, 00:00

  • HPR75 What Percent of the Growth in Annual French Social Health Insurance Budget Is Attributed to New Health Products? An Estimation Based on a Retrospective Review of Budget Impact Analyses

    Dec 1, 2023, 00:00

  • EE238 Cost-Effectiveness of Online Cognitive Behavioral Therapy for Children with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) Compared to Online Activity Management: FITNET-NHS Trial Findings

    Dec 1, 2023, 00:00

  • MT23 Hypoglossal Nerve Stimulation in Obstructive Sleep Apnea: A Systematic Literature Review

    Dec 1, 2023, 00:00

  • MSR127 How to Estimate 95% Confidence Intervals When Combining Bootstrapping and Multiple Imputation in Economic Evaluations: A Simulation Study

    Dec 1, 2023, 00:00

  • EPH251 Subtype Distribution of Amyloidosis in the United States: Insights from an Electronic Health Records Database Analysis

    Dec 1, 2023, 00:00

  • PT5 The Role of EUnetHTA 21 in Promoting Patient Engagement

    Dec 1, 2023, 00:00

  • EPH56 The Impact of the COVID-19 Pandemic on Cardiovascular Disease Prevention and Corresponding Geographical Inequalities in England: Interrupted Time Series Analysis

    Dec 1, 2023, 00:00

  • RWD20 Health Care Resource Utilization Patterns in Finnish Multiple Myeloma Patients: A Population-Based Cohort Study

    Dec 1, 2023, 00:00

  • Expanding Data Sources: Creative Use of Data in Health Economics Analyses

    Dec 1, 2023, 00:00

  • HTA201 Knowledge Transfer and Capability Building Program on Institutionalization and Governance of HTA Ukraine: Results and Future Perspectives

    Dec 1, 2023, 00:00

  • MSR33 Improving Analysis of Continuous Predictors: Advantages of Fractional Polynomial Transformations (FP) and Interpretation of “Non-Linear” Odds Ratios (OR) or Hazard Ratios (HR)

    Dec 1, 2023, 00:00

  • MSR24 Shaping the Value Equation in Digital Healthcare: A Holistic Perspective on Patient, System, and Provider Interactions

    Dec 1, 2023, 00:00

  • HTA2 Cost-Effectiveness of a Clinical Care Pathway for the Screening of Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus

    Dec 1, 2023, 00:00

  • Disclosure Information

    Dec 1, 2023, 00:00

  • HPR110 From Paper to Patients: Revealing the Impact of the United Kingdoms' (UK) Health Technology Assessment (HTA) Policies on Advanced Therapy Medicinal Products (ATMPS)

    Dec 1, 2023, 00:00

  • HPR149 Generic Pricing Policy Frees Up $1 Billion: Statin Pricing and Expenditure from 2010-2022 in Australia.

    Dec 1, 2023, 00:00

  • EE124 Analysis of the Use of the Haute Autorité De Santé (HAS) Opinions by Hospital Pharmacists in France

    Dec 1, 2023, 00:00

  • HTA223 Comparative Evaluation of the HTA Evidence Requirements and Outcomes for Digital Health Technologies in Germany and UK

    Dec 1, 2023, 00:00

  • EE217 Cancer-Related Mortality in Turkiye: Years of Life Lost and Productivity Costs

    Dec 1, 2023, 00:00

  • HTA16 Summary of Economic Evaluations on Onco-Hematology in France By the Has: What Did We Learn?

    Dec 1, 2023, 00:00

  • PT9 Harnessing the Potential of Natural-Language Processing and Interconnected Data Streams for Complex Diseases in the Hospital Setting: Lupus Case Study in France (LUPUS REAL)

    Dec 1, 2023, 00:00

  • HTA358 Value-Based Contracts Types Across Global Healthcare Systems: Comparing Perceptions Between Finance-Based and Outcomes-Based Agreements

    Dec 1, 2023, 00:00

  • EPH37 Burden of Disease and Cost of Illness of Age Related Macular Degeneration and Diabetic Macular Edema in Portugal

    Dec 1, 2023, 00:00

  • EE301 Consumption Value of a Quality-Adjusted Life Year: A Time Trade-Off for Income Analysis of Hungarian Cross-Sectional Data

    Dec 1, 2023, 00:00

  • PCR224 Corticosteroids Usage Impact on Inflammatory Bowel Disease Patients, in Portugal

    Dec 1, 2023, 00:00

  • HSD64 Breast Cancer in the COVID-19 Pandemic Era: An Old Tool with Modern Innovations

    Dec 1, 2023, 00:00

  • EE131 Genetic-Guided Pharmacotherapy for Cardiovascular Disease: A Systematic and Critical Review of Economic Evaluations

    Dec 1, 2023, 00:00

  • EPH120 Explaining the Differences in Social Distancing Behavior in the EU During the COVID-19 Pandemic

    Dec 1, 2023, 00:00

  • MSR11 Performance of Progression-Based and Time-to-Death Utility Analysis Methods and Their Implications on Economic Models: A Targeted Review

    Dec 1, 2023, 00:00

  • RWD142 Global Use of Nordic Real-World Eviden A Systematic Review of Published Literature and HTA Submissions

    Dec 1, 2023, 00:00

  • PCR31 Psychometric Performance of the Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Questionnaire Among Patients With Paroxysmal Nocturnal Hemoglobinuria

    Dec 1, 2023, 00:00

  • RWD145 Devastating Loss of Life Expectancy and Quality-Adjusted Life Years after Stroke in Brazil: A Focus on Hemorrhagic Subtypes

    Dec 1, 2023, 00:00

  • HSD25 Patients’ Satisfaction from Primary Healthcare Services in 1ST Local Health Unit (LHU) of N. Philadelphia-N. Chalkidona Municipality Greece

    Dec 1, 2023, 00:00

  • Psychometric Comparison of EQ-5D-Y, CHU-9D, and PedsQL 4.0 in Chinese Children and Adolescents With Functional Dyspepsia: A Multicenter Study

    Dec 1, 2023, 00:00

  • EPH273 Using Real-World Data Sources in England to Quantify the Burden of Non-Alcoholic Steatohepatitis

    Dec 1, 2023, 00:00

  • EE744 Invasive Meningococcal Disease Economic Burden: A Comprehensive Analysis

    Dec 1, 2023, 00:00

  • PT13 An Evaluation of the Impact of Evidence Grouping on Certainty Rating When Performing a Grade Assessment Without a Meta-Analysis

    Dec 1, 2023, 00:00

  • PCR11 Humanistic and Economic Burden of Multiple System Atrophy: A Systematic Review

    Dec 1, 2023, 00:00

  • MSR68 How to Choose the Right Insulin in Patients with Type 2 Diabetes: A Joint Modeling Method

    Dec 1, 2023, 00:00

  • OP19 Monoclonal Antibodies in Oncology: A Comparative Analysis of Subcutaneous Form Use Between Paris University Hospitals (AP-HP) Versus French Hospitals

    Dec 1, 2023, 00:00

  • SA19 Biologics Sequencing in Clinical Units (BISCUITS): UK IBD Registry Agile Research

    Dec 1, 2023, 00:00

  • EE380 Budget-Impact Analysis of Encorafenib with Binimetinib for Unresectable or Metastatic Melanoma in BRAFV600-Mutated Patients in an Argentinian Social Security Payer Setting

    Dec 1, 2023, 00:00

  • EE198 A Targeted Literature Review of Treatment Sequencing Approaches in Economic Analyses in Relapsing Multiple Sclerosis

    Dec 1, 2023, 00:00

  • EPH100 Public Health Impact of Switching from a 4-Valent to a 9-Valent HPV Vaccination Program in Mexico

    Dec 1, 2023, 00:00

  • RWD10 Real-World Safety and Effectiveness of Sodium Oxybate in the Management of Narcolepsy: A Systematic Literature Review

    Dec 1, 2023, 00:00

  • MT27 Does Da Vinci Multiport Experience Help a Surgeon Learn the New Da Vinci Single Port System When Performing a Radical Prostatectomy?

    Dec 1, 2023, 00:00

  • EE16 Budget Impact Analysis of the Introduction of Dexcom ONE for the Treatment of Patients With T2 Diabetes on an Intensive Insulin Schedule From the Perspective of the Italian Healthcare Payer

    Dec 1, 2023, 00:00

  • HPR25 Germany: Leading the Way for Digital Health Technology Assessment in Europe

    Dec 1, 2023, 00:00

  • PCR10 A Comparative Study of Health-Related Quality-of-Life Outcomes in Patients Undergoing Total Hip Arthroplasty in the Hungarian Public and Private Healthcare

    Dec 1, 2023, 00:00

  • EE739 Assessing the Value of Next Generation Sequencing in NSCLC

    Dec 1, 2023, 00:00

  • PT34 Impact in Health Outcomes of PD-(L)1 Inhibitors to Treat Early Stages Cancers in Switzerland

    Dec 1, 2023, 00:00

  • PCR93 Actinic Keratosis: Patient Perceptions and Expectations for Treatment (REAKT Study)

    Dec 1, 2023, 00:00

  • HTA363 Impact of ASMR Changes on List Prices: An Analysis of HAS Re-Evaluations

    Dec 1, 2023, 00:00

  • EPH206 Public Health Impact of Nirsevimab Against Lower Respiratory Infections Associated with Respiratory Syncytial Virus Among Chinese Infants

    Dec 1, 2023, 00:00

  • RWD149 Real-Life Dose Escalation of Patients with Ulcerative Colitis and Crohn’s Disease Undergoing Biologic Treatment in Portugal

    Dec 1, 2023, 00:00

  • HTA40 Making MCDA 'Shiny' With an Adaptive Support Tool for Healthcare Decision-Making: An Application in Broad Molecular Testing With R Shiny

    Dec 1, 2023, 00:00

  • HSD94 Assessing Payer Perspectives on Novel Therapies for the Treatment of Gorlin Syndrome

    Dec 1, 2023, 00:00

  • HTA13 Broadening the Scope: Analysis of Oncology Reimbursement Decisions Following the Cancer Drugs List Introduction in Singapore

    Dec 1, 2023, 00:00

  • HPR175 Estimating the Impact of the Elective Recovery Plan on Reducing Elective Waiting Lists in England

    Dec 1, 2023, 00:00

  • HPR56 Rare Disease Policies and Orphan Drug Designation Processes in European and Asia-Pacific (APAC) Countries

    Dec 1, 2023, 00:00

  • HSD68 Emotions of Physicians Elicited by Their Patients’ Rare Disease Diagnoses: A Cross-Sectional Study in Europe and the United States

    Dec 1, 2023, 00:00

  • HTA320 Predicting Value and Price of Orphan Drugs: A Comparison Across Europe and the US

    Dec 1, 2023, 00:00

  • EE150 Usage of Social Return on Investment Modelling in the Analysis of Healthcare Interventions: A Review of Current Utilization

    Dec 1, 2023, 00:00

  • EE43 Utilizing Real-World Evidence to Estimate Treatment Costs Among Norwegian Patients with Myasthenia Gravis Treated with Intravenous Immunoglobulin (IVIG)

    Dec 1, 2023, 00:00

  • EE668 Cost-Effectiveness of Pembrolizumab as an Adjuvant Treatment for Adults and Adolescents Aged 12 Years and Older With Resected Stage IIB/IIC Melanoma in France

    Dec 1, 2023, 00:00

  • MSR43 Flexible Parametric and Semi-Parametric Non-Markov Multi-State Models: Estimation, Prediction Simulation

    Dec 1, 2023, 00:00

  • CO25 A Systematic Literature Review (SLR) of the Clinical Efficacy and Safety Evidence Associated with Treatment of Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS)

    Dec 1, 2023, 00:00

  • EE472 Estimation of the Burden of Chronic Kidney Disease in the Argentine Health System

    Dec 1, 2023, 00:00

  • PT6 What Do Patients Value? Development of a Preference-Based Health Utility Score for Chronic Obstructive Pulmonary Disease (COPD)

    Dec 1, 2023, 00:00

  • CO155 Trial-Level Endpoint Surrogacy Analysis: Feasibility Assessment and Comparison of Different Methodological Approaches

    Dec 1, 2023, 00:00

  • HSD108 Evaluating Electronic Therapeutic Protocols (ETPS) for Diabetes and Heart Failure in Gree Results from a Quantitative Survey Amongst Practicing Physicians

    Dec 1, 2023, 00:00

  • EE281 Predicted UK Health Care Associated Cost-Savings and Health-Related Quality of Life Benefits of Introducing a Digital Leakage Notification System for People Living with a Stoma

    Dec 1, 2023, 00:00

  • EE226 Economic Evaluation of Trastuzumab in HER2-Positive Early Breast Cancer in Indonesia: A Cost-Effectiveness Analysis

    Dec 1, 2023, 00:00

  • HTA94 Challenges Facing the Health Technology Assessment (HTA) Submissions of Second Line Treatments for Advanced Oncology

    Dec 1, 2023, 00:00

  • MSR105 Construction of External-Control Arms (ECA) in Relapsed and Refractory Multiple Myeloma (RRMM)

    Dec 1, 2023, 00:00

  • EPH53 Leave or Stay? Influencing Factors of Intention to Leave or Stay in Healthcare Profession After Coronavirus Pandemic Among Frontline Nurses

    Dec 1, 2023, 00:00

  • EE298 Process and Results of the Third Update of the Dutch Guideline for Economic Evaluations in Healthcare: Evolution Instead of Revolution

    Dec 1, 2023, 00:00

  • EE459 Lifetime Healthcare and Long-Term Care Use of Heart Failure Patients in the Netherlands

    Dec 1, 2023, 00:00

  • EPH244 Late-Stage Cancer Diagnosis and Systemic Therapy in England Since 2018

    Dec 1, 2023, 00:00

  • PCR270 Development of a Quality Appraisal Tool for Systematic Literature Reviews of Studies Eliciting Health State Utility Values (HSUVs): A Delphi Consensus Approach

    Dec 1, 2023, 00:00

  • HTA24 Are the Hurdles Too High for Access to Gene Therapies in the UK?

    Dec 1, 2023, 00:00

  • EPH30 Impact of Paternal Treatment on Birth Outcomes Among Individuals with Autoimmune Rheumatic Diseases

    Dec 1, 2023, 00:00

  • EE620 Increase in HCM-Related Economic Burden Due to Atrial Fibrillation in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: A Claims Analysis of 9490 Patients

    Dec 1, 2023, 00:00

  • EE255 The Budget Impact of Switching From High to Low Carbon Emission Inhalers in England

    Dec 1, 2023, 00:00

  • PT40 Epidemiology and Burden of Illness of Lupus in Children by Form of Lupus: A Retrospective Longitudinal National Hospital Claims Study in France

    Dec 1, 2023, 00:00

  • SA5 Innovative Direct-to-Physician Retrospective Chart Review Approach: Synthesized Learnings from Completed and Ongoing

    Dec 1, 2023, 00:00

  • RWD58 Impact of Bleeds on the Quality of Life of Patients with Haemophilia: Results from a Multinational Real-World Survey

    Dec 1, 2023, 00:00

  • EE571 Indirect Costs and Out-of-Pocket Expenses of Chronic Kidney Disease on Dialysis in Bogota, Colombia

    Dec 1, 2023, 00:00

  • HPR99 Regional Access Timelines in Italy: Factors Affecting Speed and Equity

    Dec 1, 2023, 00:00

  • EE726 Economics Costs Associated with Hyperkalemia in Argentina

    Dec 1, 2023, 00:00

  • MSR39 The Performance of Anchored and Unanchored Population Adjustment Methods (MATCHING-ADJUSTED INDIRECT COMPARISON, SIMULATED TREATMENT COMPARISON, AND MULTIPLE IMPUTATION MARGINALIZATION) in Castration Resistant Prostate Cancer

    Dec 1, 2023, 00:00

  • EPH58 The Risk of First and Recurrent Mace Associated with Elevated Lp(A) in a Primary Prevention Population

    Dec 1, 2023, 00:00

  • CO154 Evaluating Patients Perception of Generic Medicines in Greece

    Dec 1, 2023, 00:00

  • HTA172 Value of French Framework for Early Access Programs for the HTA Appraisal in the Rare Disease Spa The Example of Lanadelumab in Patients With Hereditary Angioedema

    Dec 1, 2023, 00:00

  • EE543 Cost and Opportunity in Hemophilia: The Economic Impact of Drug Treatment

    Dec 1, 2023, 00:00

  • MSR35 Beyond HbA1c: A Contemporary Approach to Modelling Type 2 Diabetes Within the Updated Cardiff T2D Model

    Dec 1, 2023, 00:00

  • PCR59 Self-Reported Health Status and Its Predictors Among People with Diabetes in France

    Dec 1, 2023, 00:00

  • EE24 Budget Impact of Stepping Off Patients from Long-Term Inappropriate Proton Pump Inhibitors (PPIs) Use to Episodic Alginate Treatment

    Dec 1, 2023, 00:00

  • RWD90 How to Reduce the Burden of Travel for the Patients? a Proof of Concept (POC) for Oncological Oral Drugs Distribution Points Analysis

    Dec 1, 2023, 00:00

  • EE513 Cost-Effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed or Refractory Large B-Cell Lymphoma—Exploring the Impact of Country Settings and Performance-Based Managed Entry Agreements

    Dec 1, 2023, 00:00

  • EE142 Healthcare Resource Use and Costs Associated with Herpes Zoster/Post-Herpetic Neuralgia Episodes in Italy: A Retrospective Observational Study

    Dec 1, 2023, 00:00

  • EPH67 Epidemiology and Economic Burden of Tick-Borne Encephalitis Hospitalizations in Mainland Fran 2014-2021 Analysis of the PMSI Database

    Dec 1, 2023, 00:00

  • PCR21 Patient Preferences and Expectations Regarding Leukemia and Lymphoma Treatment: Improving Patient Engagement in Portugal through Quantitative and Qualitative Findings

    Dec 1, 2023, 00:00

  • EE734 Cost Consequences of Using Clevidipine in Cardiac Surgery from the Perspective of a US Hospital

    Dec 1, 2023, 00:00

  • HSD102 Preferences of Nurses for Attributes of Pediatric Hexavalent Vaccines in the United Kingdom

    Dec 1, 2023, 00:00

  • EE63 Cost-Effectiveness of Olaparib Plus Bevacizumab First-Line Maintenance in Ovarian Cancer Alongside the PAOLA-1 Trial

    Dec 1, 2023, 00:00

  • EE561 The Comparative Pharmacoeconomic Analysis of Using Different Anti-VEGF Drugs for Diabetic Macular Edema Therapy in Russia

    Dec 1, 2023, 00:00

  • EPH170 Epidemiology of Stroke in Bulgaria

    Dec 1, 2023, 00:00

  • OP29 A Comparative Study of Patient Safety Culture Between 2013 and 2019 at a University Hospital in a Rural Area in Japan

    Dec 1, 2023, 00:00

  • HPR138 How Are Patient Experience Data Reported in Regulatory Evaluation of Medicinal Products? A Document Analysis of European Public Assessment Reports

    Dec 1, 2023, 00:00

  • HSD3 Treatment and Associated Outcomes of Type-2 Diabetes Mellitus Patients With a Cardiovascular Comorbidity and Comparison With Guideline Recommendations: A German Claims Data Analysis

    Dec 1, 2023, 00:00

  • HTA225 New HTA Model for Digitally Supported Managed Care: Lessons From Parkinson's Disease

    Dec 1, 2023, 00:00

  • HSD124 Treatment Patterns in Pediatric Patients with Atopic Dermatitis

    Dec 1, 2023, 00:00

  • EE35 Social and Economic Burden of Hepatitis C in Russia

    Dec 1, 2023, 00:00

  • HPR221 A Reconstruction and Validation of the Rationale Underlying the Ec Proposal to Make Regulatory Data Protection (RDP) Conditional upon Supply in EU Member States

    Dec 1, 2023, 00:00

  • CO9 Post-Discharge Mortality in Patients with Mental Illness Hospitalized Compulsorily in Accordance with the Provisions of Article 29 of the Japanese Mental Health and Welfare Law

    Dec 1, 2023, 00:00

  • RWD17 Methodology for the Development of a Data Collection Tool

    Dec 1, 2023, 00:00

  • EE499 Cost-Effectiveness Analysis of Using the Fixed-Dose Combination of Levodopa/Carbidopa/Entacapone in Patients With Parkinson’s Disease in Kazakhstan

    Dec 1, 2023, 00:00

  • PCR198 Should We be Mapping from Sleep-Specific to Generic Preference-Based Quality-of-Life Instruments? Unravelling the Debate with a Multi-Instrument Mapping Study of 6 Sleep-Specific and 4 Preference-Based Instruments

    Dec 1, 2023, 00:00

  • HPR176 Exploring Diverse Health Financing Models in Europe

    Dec 1, 2023, 00:00

  • HTA127 No Half Measures: Health Inequalities in Technology Appraisal

    Dec 1, 2023, 00:00

  • HTA249 The Use of Preprints in Health Technology Assessment during Sars-Cov-2 Pandemic

    Dec 1, 2023, 00:00

  • RWD133 Cross Sectional Claims Data Analysis on Myopia Epidemiology and Treatment Options in Germany

    Dec 1, 2023, 00:00

  • EE352 A Budget Impact Analysis of Cladribine in England and Wales for Patients With Highly Active Relapsing-Remitting Multiple Sclerosis (HA-RRMS)

    Dec 1, 2023, 00:00

  • EPH62 Impact of Ethnicities on the Risk of Type 2 Diabetes in Women With a History of Gestational Diabetes: Results of a Systematic Review and Meta-Analysis

    Dec 1, 2023, 00:00

  • PCR29 Progressive Disease Milestones and Survival in Duchenne Muscular Dystrophy (DMD): A Model-Based Synthesis for Extrapolating Lifetime Treatment Effects From Clinical Trial Results

    Dec 1, 2023, 00:00

  • RWD14 Endometrial Cancer First Line Treatment in Argentina: ECHOS-A Real-World Study

    Dec 1, 2023, 00:00

  • CO162 More Serbia: Molnupiravir Real World Utilization Among COVID-19 Patients in Serbia

    Dec 1, 2023, 00:00

  • HTA167 Another Hurdle in Anticancer New Drug Listing in Korea—Setting the Reimbursement Scope

    Dec 1, 2023, 00:00

  • MSR79 Matching Plus Regression Adjustment for the Estimation of the Average Treatment Effect on Survival Outcomes: A Case Study with Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma

    Dec 1, 2023, 00:00

  • HSD131 Long-Term Impact of a Comprehensive Care Coordination Program on Medicaid Expenditures Among Children and Young Adults with Chronic Diseases

    Dec 1, 2023, 00:00

  • HPR158 Challenges, Opportunities and Policy Ways Forward to Systematically Embed the Use of Patient Experience Data in Healthcare Decision-Making: Insights From Multi-Stakeholder Interviews

    Dec 1, 2023, 00:00

  • CO23 How Immunotherapies Have Altered the Future of Cancer Treatment: Patients Living Longer, Healthier Lives

    Dec 1, 2023, 00:00

  • EE606 Tools for the Critical Appraisal of Health Economic Analyses: A Scoping Review

    Dec 1, 2023, 00:00

  • EE19 Cost Utility Analysis of the Flash Glucose Monitoring System in the Management of People With Type 2 Diabetes Mellitus on Basal Insulin Therapy—An Italian Healthcare System Perspective

    Dec 1, 2023, 00:00

  • MSR156 Evaluating Bias Associated With Inadequate Variable Selection When Using Inverse Probability of Censoring Weights to Adjust for Treatment Switches in Clinical Trials

    Dec 1, 2023, 00:00

  • HTA287 Impact of the 2020 Update of the French Guidelines for Economic Evaluation on the Economic Opinions Issued By the Economic Evaluation and Public Health Committee (CEESP)

    Dec 1, 2023, 00:00

  • EPH193 The Role of Adjuvant Atezolizumab in Reducing Recurrence-Related Treatment Costs in Resected Early-Stage PD-L1 High Non-Small Cell Lung Cancer across Europe

    Dec 1, 2023, 00:00

  • PCR66 Psychometric Validation of PROMIS-Fatigue-MS-8a Questionnaire in Relapsing Multiple Sclerosis Patients Participating in a Phase 2 Study of Frexalimab

    Dec 1, 2023, 00:00

  • EE22 Hybrid Closed Loops – A Cost-Effective Future for Type 1 Diabetes Standard of Care? An Update to the TA10845 Economic SLR

    Dec 1, 2023, 00:00

  • SA67 Considerations for Including Different Routes of Administration in Network Meta-Analysis: A Comprehensive Review

    Dec 1, 2023, 00:00

  • RWD35 Health Status Changes of Refugees from North Korea After Defection: Using National-Wide Big Data in South Korea

    Dec 1, 2023, 00:00

  • P3 Open-Source Model Framework for Health-Economic Evaluation of Early Treatment in Alzheimer's Disease

    Dec 1, 2023, 00:00

  • HTA100 Health Technology Assessment Paradigm in Rare Diseases: Critical Determinants and Recommendations

    Dec 1, 2023, 00:00

  • CO138 Outcomes and Health-Related Costs of Patients with Unresectable Stage III Non-Small Cell Lung Cancer in the Brazilian Public Health System

    Dec 1, 2023, 00:00

  • HTA179 Environmental Impact and Health Technology Assessment: State of Art and Future Perspectives

    Dec 1, 2023, 00:00

  • HPR131 What Is a Year of Life Worth? Empirical Findings from Worldwide Economic Studies on the Value of a Statistical Life

    Dec 1, 2023, 00:00

  • HSD13 The Impact of Co-Locating GP-Led Minor Injury Clinic on Pediatric Emergency Department

    Dec 1, 2023, 00:00

  • MSR86 Use of Data Linkage for the Evaluation of Medical Devices: A Systematic Literature Review

    Dec 1, 2023, 00:00

  • HPR59 Evolving Global Regulatory Landscape for Approval of Biosimilars: A Structured Literature Review on Current Challenges and Future Considerations

    Dec 1, 2023, 00:00

  • HPR38 Arbitral Awards on Reimbursement Prices Since 2019 in Germany: What We Can Learn?

    Dec 1, 2023, 00:00

  • CO21 Matching Adjusted Indirect Comparison (MAIC) of Selpercatinib Vs Cabozantinib in RET Mutation-Positive Advanced Medullary Thyroid Cancer (MTC)

    Dec 1, 2023, 00:00

  • PCR154 How and Why Do Multimorbid Patients Adhere to Their Medications? A Qualitative Study Looking Beyond the Risk-Benefit Scale

    Dec 1, 2023, 00:00

  • EE658 Cost-Consequence of Cladribine Tablets for the Treatment of Highly-Active Relapsing-Remitting Multiple Sclerosis (RRMS) in the UK

    Dec 1, 2023, 00:00

  • CO77 Impact of Imetelstat Treatment on PROs and Health Care Resource Utilization in Heavily Transfused Non-Del(5Q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory to Erythropoiesis Stimulating Agents: IMerge Phase 3 Trial

    Dec 1, 2023, 00:00

  • PCR135 Selecting Preference-Based Measures (PBMS) for Pediatric Studies: A Proposed Decision Making Framework

    Dec 1, 2023, 00:00

  • EE560 A Comparison of Time-Driven Activity-Based Costs for Patients and Caregivers Receiving Intravitreal Treatments for Neovascular Age-Related Macular Degeneration

    Dec 1, 2023, 00:00

  • EPH165 Assessing Public Health Models in Fran A Systematic Review

    Dec 1, 2023, 00:00

  • RWD169 Resource Utilization of Different Remission and Relapse Profiles in Chronic Urticaria—Results From Predict-CSU Real-World Study in the United States

    Dec 1, 2023, 00:00

  • EE39 Loss of Productivity, Use of Healthcare Resources and Cost Associated with Insomnia

    Dec 1, 2023, 00:00

  • HTA177 The Safety and Effectiveness of Root Membrane Technique (Socket Shield Technique)

    Dec 1, 2023, 00:00

  • CO98 Health Outcomes and Cost-Effectiveness of Atezolizumab in Small Cell Lung Cancer

    Dec 1, 2023, 00:00

  • CO72 Vitamin D as an Adjunct Therapy in the Treatment of Atopic Dermatitis: A Targeted Review

    Dec 1, 2023, 00:00

  • EE33 Targeted Literature Review on the Economic and Quality of Life Burden Caused by Acne

    Dec 1, 2023, 00:00

  • EE484 Multinational Real-World Data in Transplant Patients with Refractory/Resistant Cytomegalovirus Infection Enhance Cost-Effectiveness Modelling Outcomes

    Dec 1, 2023, 00:00

  • HSD101 Development of an Adjusted Outpatient Surgery Index (AOSI) Using Machine Learning Methods

    Dec 1, 2023, 00:00

  • EE555 Economic Burden of Cardiorespiratory Hospitalizations Associated With RSV Among US Adults, 2017-2019

    Dec 1, 2023, 00:00

  • EE704 Risdiplam for the Treatment of Spinal Muscular Atrophy: Impact on the National Healthcare Service During the First 15 Months of Commercialization in Italy

    Dec 1, 2023, 00:00

  • PCR8 Perceived Barriers to HIV Prevention and Detection Among Adolescents and Young People, According to Civil Organization Leaders and Health Professionals in Chile

    Dec 1, 2023, 00:00

  • EE105 anti-VEGFs Use in Neovascular Age-Related Macular Degeneration: An Analysis of the National Report on Medicines Use in Italy

    Dec 1, 2023, 00:00

  • HTA88 Reimbursement of CAR-T Cell Therapies in Europe: Key Challenges from Precedents and Lessons for Future

    Dec 1, 2023, 00:00

  • SA53 The Accuracy of Network Meta-Analysis Feasibility Predictions Based on Data Included Only in the Abstracts of Trial Publications

    Dec 1, 2023, 00:00

  • CO173 Outcomes, Treatment Pattern, and Related Cost of Late-Stage Non-Small Cell Lung (NSCLC) Cancer in Taiwan

    Dec 1, 2023, 00:00

  • MSR19 Disease Diagnosis and Severity Prediction: Artificial Intelligence Applications in Hemophilia A

    Dec 1, 2023, 00:00

  • PCR164 Feasibility and Validation of the Japanese Version of the EQ-HWB

    Dec 1, 2023, 00:00

  • EE299 The Absence of Risk Preferences in Health Economics – What Can We Learn From Transport Economics?

    Dec 1, 2023, 00:00

  • HTA140 The in Need of Medicines Fund: Analysis of NICE Technology Appraisals to Explore Barriers to Managed Access Via the IMF

    Dec 1, 2023, 00:00

  • MSR134 The Impact of Loneliness on Health Service Use and Health-Related Quality of Life Among Informal Carers in Australia

    Dec 1, 2023, 00:00

  • HPR31 Is the UK’S Ilap Process Delivering Its Intended Benefits? a Review of Access to Orbis Designated Oncology Products within the UK

    Dec 1, 2023, 00:00

  • PCR168 Diabetes Mellitus Type 1 in Chile: Unveiling the Patient Journey Throughout Coverage Schemes in Young People and Adults

    Dec 1, 2023, 00:00

  • OP22 Content Analysis of Drug Recall Announcements in Saudi Arabia: Between 2016 and 2022

    Dec 1, 2023, 00:00

  • RWD91 Hospital Efficiency Impact of Spectral CT Versus Conventional CT in Diagnosis of Patients Suspected of Occult Cancer in the UK

    Dec 1, 2023, 00:00

  • PCR35 Health-Related Quality of Life and Its Drivers for Patients Living With Cystic Fibrosis in Five Key European Countries: A Systematic Review

    Dec 1, 2023, 00:00

  • HTA137 Determining Relevant Thresholds for Reimbursement of Healthcare Interventions: Should We Prohibit the Use of the QALY at Last?

    Dec 1, 2023, 00:00

  • EPH82 Real-World Outcomes in Patients with Resected Non-Small Cell Lung Cancer (NSCLC) Receiving (NEO)Adjuvant Treatment in Germany: An I-O Optimise Analysis

    Dec 1, 2023, 00:00

  • MSR85 Psoriasis Symptoms and Impacts Measure: Identifying Key Items Reflecting Core Symptoms of Patients with Plaque Psoriasis

    Dec 1, 2023, 00:00

  • SA30 A Systematic Review of the Use of Registry-Based Randomized Controlled Trials (R-RCTs) for Regulatory Approval and Access

    Dec 1, 2023, 00:00

  • MSR26 The Use of Copilot, a Generative Artificial Intelligence Tool, as VBA Programming Assistant in Excel-Based Health Economic Models

    Dec 1, 2023, 00:00

  • EE345 Clinical and Economic Impact Analysis of Viscosupplementation With Hylan G-F 20 Versus Hyaluronic Acid for the Treatment of Knee Osteoarthrosis in Colombia

    Dec 1, 2023, 00:00

  • HTA341 Egyptian Guidelines for Pharmacoeconomic Evaluations: Toward Standardization of Drug Reimbursement Applications

    Dec 1, 2023, 00:00

  • EPH75 Adverse Event Types and Discontinuation Rate of Alzheimer's Medication Approved by United States Food and Drug Administration (USFDA)

    Dec 1, 2023, 00:00

  • HTA261 Preparing for the EU Regulation on HTA and Joint Clinical Assessments of Vaccines

    Dec 1, 2023, 00:00

  • EE48 Healthcare Resource Utilization (HCRU), Quality of Life (QoL), and Employment Changes for Early, Middle and Late-Stage People with Amyotrophic Lateral Sclerosis (pALS) in Italy: Results from a Real-World Survey

    Dec 1, 2023, 00:00

  • HPR4 Transferable Exclusivity Vouchers: A Silver Bullet?

    Dec 1, 2023, 00:00

  • MSR27 Inter-Reviewer Reliability of Literature Screening and Data Extraction for Human and Machine-Assisted Systematic Reviews

    Dec 1, 2023, 00:00

  • EPH118 Elevated Amputation Rates in Painful Diabetic Polyneuropathy: Insights from a Real-World Large Payer Data Set

    Dec 1, 2023, 00:00

  • EE159 Cost-Effectiveness Analysis of an Adjusted Polygenic Risk Score in Cardiovascular Disease Prevention

    Dec 1, 2023, 00:00

  • PCR71 Using Schedule for the Evaluation of Individual Quality of Life (SEIQoL) and Computer Adapted Testing (CAT) in Current Practices

    Dec 1, 2023, 00:00

  • EE179 Economic Burden and Health-Related Quality of Life Among Older People With Dementia Living at Home and Their Informal Caregivers in the Milan Metropolitan Area

    Dec 1, 2023, 00:00

  • PT35 Matching-Adjusted Indirect Comparison (MAIC) of Dabrafenib Plus Trametinib Versus Pembrolizumab Plus Chemotherapy in Patients with Treatment-Naive Metastatic BRAF V600 Mutation-Positive Non-Small Cell Lung Cancer (NSCLC)

    Dec 1, 2023, 00:00

  • EE379 Economic Evaluation of Nubeqal for the Treatment of Adult Patients With Non-Metastatic Castration Resistant Prostate Cancer in the Mexican Context

    Dec 1, 2023, 00:00

  • PCR165 Accessibility Vs Standardization: A Study of Electronic Implementation of Patient-Reported Outcomes Measures with Vision-Impaired Participants

    Dec 1, 2023, 00:00

  • HPR180 Evaluating the Success of the National Bundle Payment Program for Osteoarthritis

    Dec 1, 2023, 00:00

  • HTA244 Evaluation of the Acceptance of Real-World Evidence (RWE) in Eunethta Joint Clinical Assessments (JCA) to Support Evidence for Reimbursement Decisions

    Dec 1, 2023, 00:00

  • HPR196 Loss of Exclusivity (LOE): Impact Analysis across Europe-5 and Select Nordic Countries

    Dec 1, 2023, 00:00

  • EE450 Evaluating Price Trends in Supplements from 2018 to 2022 in Turkiye

    Dec 1, 2023, 00:00

  • PCR145 Dupilumab Reduces Systemic Corticosteroid Use in Children with Uncontrolled Moderate-to-Severe Asthma Regardless of Prior Exacerbation History

    Dec 1, 2023, 00:00

  • HTA68 Trends in Northern Ireland HTA Guidance Adoption: NICE Shows Dominance over SMC and AWMSG

    Dec 1, 2023, 00:00

  • EE587 A Systematic Scoping Review to Identify Challenges in the Economic Evaluation of Prognostic and Predictive Companion Diagnostics in Personalized Medicine: The Radioval Study

    Dec 1, 2023, 00:00

  • RWD105 Identifying and Appraising Fit-for-Purpose Data Sources for Real World Evidence Studies: A Structured Approach to Conducting Data Source Feasibility Assessments

    Dec 1, 2023, 00:00

  • P15 Unraveling Acceptance of Healthcare Innovations in Neurorehabilitation: A Systematic Approach Through Health Preference Research

    Dec 1, 2023, 00:00

  • EPH262 The Preparedness and Contribution of Community Pharmacists During Public Health Crises

    Dec 1, 2023, 00:00

  • PCR157 Assessment of Health State Utilities for Invasive Pneumococcal Disease, Pneumonia, and Acute Otitis Media in Young Children

    Dec 1, 2023, 00:00

  • RWD31 The Impact of Advanced Training on Operational Efficiency in Robotic-Assisted Rectal Resection

    Dec 1, 2023, 00:00

  • OP25 Developments in Anticancer Drugs Preparation Activity in Hospitals Pharmacies Units (HPU) and Their Impact on the Activity of Paris University Hospitals (AP-HP)

    Dec 1, 2023, 00:00

  • PT8 Five-Year Healthcare Resource Consumption and Direct Costs of Women with a New Diagnosis of Hr+/HER2- Breast Cancer Primary or Advanced: Analysis of a Large Italian Administrative Database

    Dec 1, 2023, 00:00

  • EPH127 School Environment and Mental Health State in Brazilian Adolescents – Evaluating Public Policy Opportunities

    Dec 1, 2023, 00:00

  • SA60 Key Challenges in Gene Therapy Development for Usher Syndrome: Insights from Machine-Assisted Rapid Scoping Review

    Dec 1, 2023, 00:00

  • HTA188 The Potential Value of Health Technologies Postponing Total Knee Replacements While Increasing Patients’ Quality of Life

    Dec 1, 2023, 00:00

  • HTA286 Challenges and Solutions to Estimating Environmental Impact in Health Technology Assessment

    Dec 1, 2023, 00:00

  • CO151 Association of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists With the Risk of Developing Dementia in People With Type 2 Diabetes Mellitus

    Dec 1, 2023, 00:00

  • HTA258 A Hospital-Based Health Technology Assessment of Near-Infrared Fluorescence Using Indocyanine Green for Sentinel Lymph Node Mapping for Breast Cancer and Gynecologic Cancer

    Dec 1, 2023, 00:00

  • SA13 Can Models for Surrogate Endpoint Evaluation Be Used to Predict Generic Measures From Disease Specific Measures of Health Related Quality of Life Based on Summary Data?

    Dec 1, 2023, 00:00

  • RWD88 Investigating the Transferability, at the National Level, of Results from Hemsys, a French Multidisciplinary Concertation Meetings Database in Onco-Hematology, to Generate Real-World Evidence

    Dec 1, 2023, 00:00

  • EE549 Systematic Review of the Cost Effectiveness of Newborn Screening for Severe Combined Immunodeficiency

    Dec 1, 2023, 00:00

  • CO57 A New Approach in Network Meta-Analysis Using Blended Survival Curves to Extrapolate Long-Term Survival from Immature Data

    Dec 1, 2023, 00:00

  • SA10 The Burden of Illness of Vasomotor Symptoms Associated with Menopause

    Dec 1, 2023, 00:00

  • MSR49 Non-Systematic Literature Reviews: Can AI Enhance Current Methods?

    Dec 1, 2023, 00:00

  • MSR162 The Curse of Data Maturity in Observational Studies: Practical Advice from Protocol Development to Interpretation of Results

    Dec 1, 2023, 00:00

  • Challenges in Modeling Oncology Outcomes

    Dec 1, 2023, 00:00

  • HPR119 Assessing Health Policies in Turkiye: Expert Insights on Current Challenges and Policy Recommendations from Written Motions

    Dec 1, 2023, 00:00

  • HTA360 A Comparative Assessment of Systematic Literature Review Requirements for Health Technology Assessment, Globally

    Dec 1, 2023, 00:00

  • CO16 Effect of Daratumumab on Pneumonia in Patients with Multiple Myeloma Using Population Based Real-World Data

    Dec 1, 2023, 00:00

  • HTA134 The Impact of Non-Comparative Data for Non-Orphan Drugs on HTA and Pricing Outcomes in Germany: Can an Added Benefit Ever be Proven?

    Dec 1, 2023, 00:00

  • Study Approaches

    Dec 1, 2023, 00:00

  • MSR154 Qualitative Content Analysis for Concept Elicitation (CACE) in Clinical Outcome Assessment Development

    Dec 1, 2023, 00:00

  • HPR184 Social Determinants of Health (SDoH) and Other Predictors in Treatment Initiation with CDK4/6 Inhibitors in Medicare Patients with HR+/HER2– Metastatic Breast Cancer (MBC)

    Dec 1, 2023, 00:00

  • EE83 Cost-Utility and Budget Impact Analyses of Cervical Cancer Screening Using Self-Collected Sample Kit for HPV DNA Testing in Thailand

    Dec 1, 2023, 00:00

  • HTA365 Comparison of the Use of Real-World Evidence for Clinical Effectiveness in HTA Pre- and Post- Introduction of the NICE Framework

    Dec 1, 2023, 00:00

  • EE7 Optimizing Aortic Stenosis Management: Evaluating the Clinical and Economic Impact of Transcatheter and Surgical Valve Replacement in Taiwan

    Dec 1, 2023, 00:00

  • HTA354 Cross Analysis of HAS Conclusions Amongst Products with an Economic Opinion Posted in 2022

    Dec 1, 2023, 00:00

  • EE71 Cost-Effectiveness Analysis of Using Foundationone Liquid CDx in Patients With Advanced Non-Small Cell Lung Cancer in Whom Tissue-Based Testing Is Not Feasible

    Dec 1, 2023, 00:00

  • PCR100 Vascular Access Adverse Events: A Comprehensive Literature Review and Comparative Analysis

    Dec 1, 2023, 00:00

  • HSD70 Economic Benefit of Empowering Community Pharmacists in the Diagnosis and Treatment of Acute Sore Throat in England

    Dec 1, 2023, 00:00

  • CO29 Real-World Benefit of Ataluren Treatment in Milestones Not Related to Ambulatory Function in Nonsense Duchenne Muscular Dystrophy Versus Standard of Care

    Dec 1, 2023, 00:00

  • HSD71 Management of Care for Patients With Actinic Keratosis in Fran Reakt Study

    Dec 1, 2023, 00:00

  • EE507 Pre-Progression Health State Utility Values From the TALAPRO-2 Clinical Trial in Patients With Metastatic Castration-Resistant Prostate Cancer Unselected for DDR Mutations

    Dec 1, 2023, 00:00

  • MSR89 Criteria and Methods Applied to Decision-Making to Embark on Late-Stage Clinical Trials With a Multi-Stakeholder Perspective

    Dec 1, 2023, 00:00

  • HPR44 Regional Inequalities in Access to Specialized Healthcare in the Brazilian Unified Health System

    Dec 1, 2023, 00:00

  • HTA60 Where Can International HTA Collaboration Add Value? the Experience of NICE

    Dec 1, 2023, 00:00

  • EPH71 Tendencies in Hospital Burn Care for Children in Germany

    Dec 1, 2023, 00:00

  • EPH226 Estimating the Future Prevalence, Costs, and Clinical Impact of Overweight and Obesity Classes I, II, and III in the UK

    Dec 1, 2023, 00:00

  • CO60 Predicting Treatment Effects from Surrogate Endpoints in First-Line (1L) Metastatic Castration-Resistant Prostate Cancer (MCRPC)

    Dec 1, 2023, 00:00

  • EE502 Budget Impact Analysis of Transanal Irrigation for the Treatment of Low Anterior Resection Syndrome in Spain

    Dec 1, 2023, 00:00

  • PCR125 Unmet Needs of People with Multiple Sclerosis: Findings for an Improvement of the Patient Journey in Portugal

    Dec 1, 2023, 00:00

  • SA37 A Real-World Evaluation of People with Drug-Resistant Focal Epilepsy Across Six European Countries

    Dec 1, 2023, 00:00

  • HTA170 Assessing the Impact of the NICE Methods Review on Rare Diseases

    Dec 1, 2023, 00:00

  • SA2 A Meta-Regression Tool: Assessing the Relationship Between Risk Factors and Events Development

    Dec 1, 2023, 00:00

  • MSR22 Standardized Contrasts Across Trials in Individual Patient Data Meta-Analysis With Time-to-Event Outcomes

    Dec 1, 2023, 00:00

  • PT45 Disease Relapse and Adverse Events During the Combination Use of Clozapine and Long-Acting Injectable Antipsychotics and During the Clozapine Monotherapy

    Dec 1, 2023, 00:00

  • EE604 Cost-Effectiveness Analysis of Single-Inhaler Triple Therapy (FF/UMEC/VI) in COPD Using the Impact Trial: China Medical Insurance System Perspective

    Dec 1, 2023, 00:00

  • RWD98 Health Care Resource Use and Costs of Hemophilia A in France

    Dec 1, 2023, 00:00

  • EE523 Is Dismissing Intervention Development Costs a Fallacy? a Case Study of a Digital Health Intervention E-MAT

    Dec 1, 2023, 00:00

  • MSR135 Do You Really Need to See the Doctor? Developing a Machine Learning Approach for Optimal Assignment Rules of Physician Visits for Patients After Knee Replacement

    Dec 1, 2023, 00:00

  • EPH93 Progression From Cutaneous to Systemic Lupus Erythematosus: A Systematic Literature Review

    Dec 1, 2023, 00:00

  • EE500 An Overview of Systematic Literature Review of Economic Evaluation of Treatment on Patients With Alzheimer's Disease and Related Dementia

    Dec 1, 2023, 00:00

  • EE630 The Economic Burden of Obesity in 4 Selected South-Eastern European Countries: Healthcare Resource Use and Costs Associated with Obesity-Related Comorbidities

    Dec 1, 2023, 00:00

  • HTA124 Can You Have a Common Approach to the Statistical Analysis Plan When Conducting Real-World Evidence Studies to Meet Multi-HTA Requirements?

    Dec 1, 2023, 00:00

  • RWD7 Graphical Representation of Real-World Data for Analysing Infection Outbreaks Within a Tertiary Hospital Setting: A Data-Driven Approach

    Dec 1, 2023, 00:00

  • CO51 Safety Profile of Approved Alzheimer's Medication By USFDA

    Dec 1, 2023, 00:00

  • PCR216 Patient-Driven Outcome Selection (PDOS): A Patient-Focused Approach for Selecting Outcomes Using Patient-Generated Data

    Dec 1, 2023, 00:00

  • EE455 Cost Saving Potential of Rapid Microbiological Methods: Case Form Bulgaria

    Dec 1, 2023, 00:00

  • HPR100 Orphan Drugs in Algeria and Six Other Countries: A Cross Comparison Study

    Dec 1, 2023, 00:00

  • PCR271 Employing Episodic Future Thinking to Reduce the Distortion of Time Preference in Time Trade-Off Valuation

    Dec 1, 2023, 00:00

  • HPR118 The Assessment of Alternative or Abbreviated Market Access Pathways for Pharmaceutical Reimbursement in 13 European Markets

    Dec 1, 2023, 00:00

  • EE9 Cost-Effectiveness of Icosapent Ethyl for Patients at High Cardiovascular Risk with Elevated Triglycerides in Greece

    Dec 1, 2023, 00:00

  • HPR37 Squaring the Circle? Leveraging Early Access / Compassionate Use Pathways to Provide Market-Specific Real-World Evidence Before Launch

    Dec 1, 2023, 00:00

  • HTA171 The Use of Qualitative Methods in the NICE HST Deliberative Process

    Dec 1, 2023, 00:00

  • P40 Man Versus Machine: Can AI-Assisted Technology be Used to Support the Development of Economic Models?

    Dec 1, 2023, 00:00

  • EPH124 Validity of Outpatient ICD-10 Codes to Identify Respiratory Syncytial Virus (RSV) – Estimating Sensitivity and Specificity of Health Administrative Claims Data

    Dec 1, 2023, 00:00

  • PCR214 Patient Voice in Pharmaceutical Company: The Case of Patient Committee in Brazil

    Dec 1, 2023, 00:00

  • EE432 Propel® Technology – A Budget Impact Analysis in the Italian Context

    Dec 1, 2023, 00:00

  • EE710 The Environmental, Healthcare, and Societal Impact of Asthma Pathway in the UK: A Cost-of-Illness Study

    Dec 1, 2023, 00:00

  • EE303 Cost-Utility Analysis of Roflumilast Cream for Plaque Psoriasis, Including Intertriginous, From the Canadian Societal Perspective

    Dec 1, 2023, 00:00

  • EE626 Budget Impact Analysis (BIA) of Adopting Real-Time Continuous Glucose Monitoring (rt-CGM) vs Intermittent-Scanning Continuous Glucose Monitoring (is-CGM) in Patients With Type 1 Diabetes on Insulin Therapy (PWT1D) in Italy

    Dec 1, 2023, 00:00

  • EE449 Uncertainty Around HRQoL Values Is Under-Reported: Are We Misleading Decision Makers?

    Dec 1, 2023, 00:00

  • EE673 Cost-Effectiveness Analysis of Pembrolizumab for First-Line Treatment in Patients With Persistent, Recurrent, and Metastatic Cervical Cancer in the United States: Results From the Final Analysis of Trial

    Dec 1, 2023, 00:00

  • EE47 Cost of Illness Study of Migraine in Bulgarian Patients

    Dec 1, 2023, 00:00

  • P20 Matching-Adjusted Indirect Treatment Comparison (MAIC) of Teclistamab Vs Belantamab Mafodotin for the Treatment of Patients with Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)

    Dec 1, 2023, 00:00

  • EE562 What Is More Valuable Than Optimal Resource Use? The Development of Interactive Tool Visualizing the Costs and Time Consumption Related to Diabetic Macular Edema’s Intravitreal Treatments in Finland

    Dec 1, 2023, 00:00

  • EPH119 Disease Burden and Cost-of-Illness of Hepatocellular Carcinoma in Portugal: A Model-Based Analysis Considering the Barcelona Clinic Liver Cancer Disease Staging and Treatment Algorithm System

    Dec 1, 2023, 00:00

  • EE181 COVID-19 Related Work Absenteeism and Its Associated Lost Productivity Cost in Germany: A Population-Based Study

    Dec 1, 2023, 00:00

  • EE6 Expected Value of Perfect Implementation of Icosapent Ethyl (Vazkepa) in Sweden

    Dec 1, 2023, 00:00

  • EE113 The Use of Ferric Carboxymaltose for Pregnant and Postpartum Women in Brazil: Estimation of Target Poputation and Budget Impact Analysis from the Public Health Care System Perspective

    Dec 1, 2023, 00:00

  • HTA356 Bridging the Gap between National and EUNETHTA21 HTA Methods. Are Marketing Authorisation Holders Ready for Joint Clinical Assessments?

    Dec 1, 2023, 00:00

  • PCR122 Psychometric Evaluation of Multiple Sclerosis Impact Scale 29 Version 2 in Relapsing Multiple Sclerosis Patients Participating in a Phase 2 Study of Frexalimab

    Dec 1, 2023, 00:00

  • EE572 Budget Impact Analysis of the Introduction of Endo Arteriovenous Fistula System (WAVELINQ) for Hemodialysis Access Creation in Patients with End-Stage Kidney Disease

    Dec 1, 2023, 00:00

  • HTA245 UK Mechanisms to Address Rare Disease Challenges: Does the UK Go Far Enough?

    Dec 1, 2023, 00:00

  • RWD151 Evaluation of the Effect of Methodological Assumptions on Estimates of Adherence to Antipsychotics: A Real-World Data Study

    Dec 1, 2023, 00:00

  • CO88 A Matching-Adjusted Indirect Comparison of the Efficacy of Bimekizumab and Secukinumab at 52 Weeks for the Treatment of Radiographic Axial Spondyloarthritis

    Dec 1, 2023, 00:00

  • CO50 Imminent Recurrent Fracture Risk in Patients with Osteoporotic Fractures: A Nationwide Cohort Study in South Korea

    Dec 1, 2023, 00:00

  • HPR103 Potential Impacts of the EMA-HMA Join Statement Supporting Biosimilar Interchangeability in Biosimilar Access in the EU

    Dec 1, 2023, 00:00

  • HTA355 A Roadmap Towards Implementing HTA in Oman

    Dec 1, 2023, 00:00

  • MSR161 Quantifying the Impact of Exposure Prevalence and Selection Bias to Optimize Patient Selection Criteria in Post-Authorization Safety Studies

    Dec 1, 2023, 00:00

  • RWD22 Economic Burden of Moderate and Severe Hemophilia A and B in Spain, Real-World Evidence Insights from the Cost of Hemophilia in Europe: A Socio-Economic Survey II (CHESS II) Study

    Dec 1, 2023, 00:00

  • CO184 Exploring the Relationship Between Surrogate and Long-Term Outcomes in Lysosomal Storage Diseases: A Targeted Literature Review

    Dec 1, 2023, 00:00

  • EE68 Cost-Effectiveness of Second-Line Treatment for Advanced Endometrial Carcinoma in Taiwan: Lenvatinib Plus Pembrolizumab Versus Doxorubicin

    Dec 1, 2023, 00:00

  • MSR103 Translation, Cultural Adaptation, and Psychometric Testing of the Hip Disability and Osteoarthritis Outcome Score Into Yoruba Language

    Dec 1, 2023, 00:00

  • HPR183 Evaluating the Saving Potential of Lenalidomide Before and After Transition to the Reference Price System in Finland

    Dec 1, 2023, 00:00

  • HSD38 From Unpersonalized to Personalized Breast Follow-up in Clinical Practice in the Netherlands: Will Artificial Intelligence Make a Difference?

    Dec 1, 2023, 00:00

  • EE611 Economic Evaluation of Person-Centred Care Using a Digital Platform and Structure Telephone Support for People with Chronic Heart Failure and/or Chronic Obstructive Pulmonary Disease

    Dec 1, 2023, 00:00

  • HPR174 Effects of Having a Usual Source of Care with Physician on Medical Expenses in Korea

    Dec 1, 2023, 00:00

  • PCR58 Social Media Research to Understand Reported Efficacy of GLP-1 RAs for Weight Loss

    Dec 1, 2023, 00:00

  • MT61 Differences and Similarities of Health Economic Evaluation for Medical Technologies By HTA Bodies

    Dec 1, 2023, 00:00

  • EE289 Comparison of the Clinical and Economic Impact of Two COVID-19 mRNA Vaccines in High Risk Individuals in the Tokyo Prefecture

    Dec 1, 2023, 00:00

  • HSD96 Trends in the Therapeutic Management of Bullous Pemphigoid in the Real-World Setting

    Dec 1, 2023, 00:00

  • EE102 Economic Burden of Short-Acting Beta-2 Agonist Overuse Among Asthma Patients in Turkiye: A Cost Analysis with Respect to Updated Recommendations of the Global Initiative for Asthma

    Dec 1, 2023, 00:00

  • MT6 Companion Diagnostics’ Launch and Market Access Landscape: Who Are the Trend Setters and Late Adopters?

    Dec 1, 2023, 00:00

  • MT59 Overview of Approved Digital Therapeutics in Belgium

    Dec 1, 2023, 00:00

  • EE120 Cost-Effectiveness of Difelikefalin for the Treatment of Moderate to Severe Chronic Kidney Disease-Associated Pruritus (CKD-AP) in Adult Patients Receiving in-Centre Haemodialysis

    Dec 1, 2023, 00:00

  • EE653 A Health Economic Model to Assess the Effects of Introducing Home Polysomnography for the Diagnosis of Sleep Apnea in Germany

    Dec 1, 2023, 00:00

  • CO178 Understanding Physicians’ Decision-Making Practices Related to Biomarker Testing: Analysis of the Adelphi Real-World Ovarian Cancer II Disease Specific Programme (DSPTM)

    Dec 1, 2023, 00:00

  • HPR36 Volume Vs Value: Understanding the Pricing Dynamics of Multi-Indication Therapies in Weighted-Average List Price Markets

    Dec 1, 2023, 00:00

  • EE112 Economic Burden of SLE in Nordic Countries - a Systematic Literature Review (SLR)

    Dec 1, 2023, 00:00

  • HTA163 Setting Treatment Selection Criteria for Breast Cancer From a Clinician Perspective: Is It a Matter of Cost?

    Dec 1, 2023, 00:00

  • PCR230 Real-World Clinical Characteristics of Patients with Migraine Who Initiated Fremanezumab in Sweden: An Observational, Nationwide Register-Based Study

    Dec 1, 2023, 00:00

  • EPH178 Burden of the Disease and Management in COVID-19 Hospitalized Patients in MSO and Home Care in Fran COVID-Hosp Study (2020-2022)

    Dec 1, 2023, 00:00

  • EE18 Economic Burden of Type 2 Diabetes in Peru: A Cost-of-Illness Study Valuing Cost Differences Associated With the Level of Glycemic Control

    Dec 1, 2023, 00:00

  • SA78 Active Participation of Children in Health Research: Methods, Experience and Ethical Aspects

    Dec 1, 2023, 00:00

  • HPR85 Opinions on Sustainable Healthcare Financing Options for Funding New Medical Technologies in ASEAN-6

    Dec 1, 2023, 00:00

  • RWD65 Patterns of Antibiotic Prescribing in a Tertiary Hospital Using Real-World Data

    Dec 1, 2023, 00:00

  • EE667 Cost-Minimization Analysis (CMA) of Bruton Tyrosine Kinase Inhibitors (BTKi) in Adults with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

    Dec 1, 2023, 00:00

  • EE359 Cost-Effectiveness of Pembrolizumab + Chemotherapy Versus Cetuximab-Containing Regimens ‘Extreme’ and ‘TPEx’, for R/M SCCHN Patients with a CPS between 1 and 19, in Italy

    Dec 1, 2023, 00:00

  • EE639 Explorative Cost-Effectiveness Analysis of a Rapid ID/AST Solution for Patients with Bloodstream Infection

    Dec 1, 2023, 00:00

  • EE385 Cost per Outcome Analysis of Osimertinib and Atezolizumab for Adjuvant Non-Small Cell Lung Cancer EGFRm Stage II-IIIA in Two Years from Brazilian Private Health System Perspective

    Dec 1, 2023, 00:00

  • OP14 Analysis of Interregional Variability in the Market Penetration of Immuno-Oncological Drugs in Italy

    Dec 1, 2023, 00:00
  • «
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16 (current)
  • 17
  • 18
  • 19
  • 20
  • »